ARTICLE | Company News
Evotec neurology news
March 30, 2009 7:00 AM UTC
Evotec will restructure and reduce headcount by about 50 (12%) to 370 to reduce cash burn, with the majority of reductions in SG&A. The company also will discontinue early discovery projects and will no longer invest in EVT 201, a GABA A receptor agonist in Phase II testing to treat insomnia. The company's lead program is now EVT 302, a reversible monoamine oxidase B (MAO-B) inhibitor in Phase II testing for smoking cessation, with data expected next quarter. ...